CR20210587A - Inhibidores de molécula pequeña de quinasa inductora de nf-kb - Google Patents

Inhibidores de molécula pequeña de quinasa inductora de nf-kb

Info

Publication number
CR20210587A
CR20210587A CR20210587A CR20210587A CR20210587A CR 20210587 A CR20210587 A CR 20210587A CR 20210587 A CR20210587 A CR 20210587A CR 20210587 A CR20210587 A CR 20210587A CR 20210587 A CR20210587 A CR 20210587A
Authority
CR
Costa Rica
Prior art keywords
disorders
compounds
small molecule
molecule inhibitors
inducing kinase
Prior art date
Application number
CR20210587A
Other languages
English (en)
Inventor
Wenying Chai
William M Jones
Kevin D Kreutter
J Kent Barbay
Aaron T Herrmann
Alec D Lebsack
Wendy Eccles
Alexander R Rovira
Ronald L Wolin
Paul J Krawczuk
Michael D Hack
Daniel J Pippel
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR20210587A publication Critical patent/CR20210587A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con compuestos que inhiben el NIK y composiciones farmacéuticas que comprenden tales compuestos y métodos para el uso de estos. Se prevé que estos compuestos y composiciones farmacéuticas son útiles para prevenir o tratar enfermedades tales como cáncer (tal como neoplasias de células B que incluyen leucemias, linfomas y mieloma), trastornos inflamatorios, trastornos autoinmunes, trastornos inmunodermatológicos tales como pustulosis palmoplantar e hidradenitis supurativa, y trastornos metabólicos tales como obesidad y diabetes
CR20210587A 2019-05-31 2020-05-29 Inhibidores de molécula pequeña de quinasa inductora de nf-kb CR20210587A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855144P 2019-05-31 2019-05-31
US201962907833P 2019-09-30 2019-09-30
PCT/EP2020/065024 WO2020239999A1 (en) 2019-05-31 2020-05-29 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE

Publications (1)

Publication Number Publication Date
CR20210587A true CR20210587A (es) 2022-02-11

Family

ID=71108552

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210587A CR20210587A (es) 2019-05-31 2020-05-29 Inhibidores de molécula pequeña de quinasa inductora de nf-kb

Country Status (22)

Country Link
US (3) US11254673B2 (es)
EP (1) EP3976597A1 (es)
JP (1) JP2022534302A (es)
KR (1) KR20220027871A (es)
CN (1) CN114222737A (es)
AU (1) AU2020282005A1 (es)
BR (1) BR112021023796A2 (es)
CA (1) CA3143350A1 (es)
CL (1) CL2021003142A1 (es)
CO (1) CO2021017838A2 (es)
CR (1) CR20210587A (es)
DO (1) DOP2021000244A (es)
EC (1) ECSP21093623A (es)
IL (1) IL288387A (es)
JO (1) JOP20210318A1 (es)
MA (1) MA56038A (es)
MX (1) MX2021014679A (es)
PE (1) PE20220768A1 (es)
SG (1) SG11202112994WA (es)
TW (1) TW202110842A (es)
UY (1) UY38721A (es)
WO (1) WO2020239999A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38721A (es) * 2019-05-31 2020-11-30 Janssen Pharmaceutica Nv INHIBIDORES DE MOLÉCULAS PEQUEÑAS DE QUINASA INDUCTORA DE NF-kB
CN114502540A (zh) 2019-05-31 2022-05-13 医肯纳肿瘤学公司 Tead抑制剂和其用途
WO2023217906A1 (en) * 2022-05-11 2023-11-16 Janssen Pharmaceutica Nv Pyrrolidinone derivatives as inhibitors of nf kappa b inducing kinase
WO2023217879A1 (en) * 2022-05-11 2023-11-16 Janssen Pharmaceutica Nv Pyrrolidione derivatives as inhibitors of nf kappa b inducing kinase
WO2024133302A1 (en) 2022-12-22 2024-06-27 Boehringer Ingelheim International Gmbh Crystalline forms of a her2 inhibitor

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US7132428B2 (en) 2003-07-03 2006-11-07 Aventis Pharmaceuticals Inc. Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders
TW200605886A (en) * 2004-08-03 2006-02-16 Wyeth Corp Indazoles useful in treating cardiovascular diseases
KR101227228B1 (ko) 2004-11-12 2013-01-28 스태츠 칩팩, 엘티디. 와이어 본드 배선
US20110086834A1 (en) 2008-06-26 2011-04-14 Amgen Inc. Alkynyl alcohols as kinase inhibitors
US20110183975A1 (en) 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
TW201247650A (en) 2011-03-16 2012-12-01 Hoffmann La Roche 6,5-heterocyclic propargylic alcohol compounds and uses therefor
AR089999A1 (es) 2012-02-17 2014-10-01 Hoffmann La Roche Compuestos triciclicos y metodos para el uso de los mismos
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
CN105658639A (zh) * 2013-08-22 2016-06-08 豪夫迈·罗氏有限公司 炔基醇和应用方法
WO2015025025A1 (en) 2013-08-22 2015-02-26 F. Hoffmann-La Roche Ag Alkynyl alcohols and methods of use
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
US9981962B2 (en) 2014-10-23 2018-05-29 Janssen Pharmaceutica Nv Pyrazole derivatives as NIK inhibitors
BR112017007715B1 (pt) 2014-10-23 2023-04-11 Janssen Pharmaceutica N.V. Derivados de tienopirimidina como inibidores de nik, seu uso no tratamento ou prevenção de câncer e composição farmacêutica que os compreende
CA2960574C (en) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Pyrazolopyrimidine derivatives as nik inhibitors
BR112017008045A2 (pt) 2014-10-23 2017-12-19 Janssen Pharmaceutica Nv compostos como inibidores de nik
JP2018510140A (ja) 2015-02-25 2018-04-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アルキニルアルコール及び使用方法
EP3405464B1 (en) 2016-01-22 2019-12-04 Janssen Pharmaceutica NV New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
CN108697710B (zh) 2016-01-22 2022-02-18 杨森制药有限公司 作为nik抑制剂的新颖的经取代的氰基吲哚啉衍生物
ES2805976T3 (es) 2016-06-30 2021-02-16 Janssen Pharmaceutica Nv Derivados heteroaromáticos en calidad de inhibidores de NIK
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
CN109863142B (zh) 2016-08-24 2022-06-10 豪夫迈·罗氏有限公司 2-氮杂双环[3.1.0]己烷-3-酮衍生物及使用方法
WO2018037059A1 (en) 2016-08-24 2018-03-01 F. Hoffmann-La Roche Ag 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
EP3649127B1 (en) 2017-07-06 2021-09-08 Janssen Pharmaceutica NV Substituted azaindoline derivatives as nik inhibitors
CN109810110B (zh) * 2017-11-22 2023-01-24 中国科学院上海药物研究所 一种具有2-氨基嘧啶结构的化合物，其制备方法和用途
JP2022534426A (ja) 2019-05-31 2022-07-29 イケナ オンコロジー， インコーポレイテッド Ｔｅａｄ阻害剤およびその使用
UY38721A (es) * 2019-05-31 2020-11-30 Janssen Pharmaceutica Nv INHIBIDORES DE MOLÉCULAS PEQUEÑAS DE QUINASA INDUCTORA DE NF-kB
CR20210629A (es) 2019-05-31 2022-03-22 Sage Therapeutics Inc Esteroides neuroactivos y composiciones de estos
CN114502540A (zh) 2019-05-31 2022-05-13 医肯纳肿瘤学公司 Tead抑制剂和其用途
AU2020285336A1 (en) 2019-05-31 2022-01-06 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as P2X3 inhibitors
AR120109A1 (es) 2019-09-30 2022-02-02 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores

Also Published As

Publication number Publication date
CL2021003142A1 (es) 2022-08-19
US11827634B2 (en) 2023-11-28
UY38721A (es) 2020-11-30
CA3143350A1 (en) 2020-12-03
EP3976597A1 (en) 2022-04-06
BR112021023796A2 (pt) 2022-02-08
JOP20210318A1 (ar) 2023-01-30
DOP2021000244A (es) 2022-04-18
MA56038A (fr) 2022-04-06
ECSP21093623A (es) 2022-01-31
US20230080834A1 (en) 2023-03-16
US20210300918A1 (en) 2021-09-30
JP2022534302A (ja) 2022-07-28
PE20220768A1 (es) 2022-05-16
SG11202112994WA (en) 2021-12-30
MX2021014679A (es) 2022-04-06
AU2020282005A1 (en) 2021-12-23
CN114222737A (zh) 2022-03-22
TW202110842A (zh) 2021-03-16
CO2021017838A2 (es) 2022-01-17
KR20220027871A (ko) 2022-03-08
WO2020239999A1 (en) 2020-12-03
IL288387A (en) 2022-01-01
US20240199605A1 (en) 2024-06-20
US11254673B2 (en) 2022-02-22

Similar Documents

Publication Publication Date Title
MX2021014679A (es) Inhibidores de molécula pequeña de quinasa inductora de nf-kb.
EA033343B1 (ru) Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
MX2022016434A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX2021007651A (es) Inhibidores de ezh2 para tratar linfomas.
PH12018501567A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
MX371150B (es) NUEVOS DERIVADOS DE PIRAZOL EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK).
SA519410320B1 (ar) مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل
MX2017005282A (es) Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik).
MX371152B (es) Nuevos derivados de pirazolopirimidina como inhibidores de la cinasa inductora de nf-kb (nk).
GEP20227442B (en) Boron containing pde4 inhibitors
ZA202301066B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
MX2019014665A (es) Nuevos derivados de azaindolina sustituida como inhibidores de nik.
MX2017014752A (es) Nuevos etinos de amidoheteroaril aroil hidrazida.
BR112021022966A2 (pt) Método para reduzir o tamanho do tumor
EA201500736A1 (ru) Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов
MX2021005273A (es) Inhibidores de quinasa rock.
MX2020013805A (es) Derivados de piridopirimidinona para uso como inhibidores de axl.
EA201891687A9 (ru) Новые замещённые производные цианиндолина в качестве nik-ингибиторов
MX2016013108A (es) Nueva composicion para el tratamiento de la tricomoniasis.
MY192305A (en) Bipyrazole derivatives as jak inhibitors
MY198316A (en) Piperidin-4-YL Azetidine Derivatives as JAK1 Inhibitors